Loss of exon 4 in a human T-cell factor-4 isoform promotes hepatic tumourigenicity

Liver International

Volumn 33, Issue 10, 2013, Pages 1536-1548

  Tomimaru, Yoshito ^a   Xu, Chelsea Q ^a   Nambotin, Sarah B ^a   Yan, Tao ^a   Wands, Jack R ^a   Kim, Miran ^a  

^a Liver Research Center Brown University Medical School   (United States)

Author keywords

Exon 4; Hepatocellular carcinoma; Isoform; T cell factor 4; Wnt

Indexed keywords

BETA CATENIN; DOXORUBICIN; FLUOROURACIL; ISOPROTEIN; MESSENGER RNA; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4C; T CELL FACTOR PROTEIN 4D; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLONAL VARIATION; COLONY FORMATION; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; THERAPY RESISTANCE; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EXON 4; HEPATOCELLULAR CARCINOMA; ISOFORM; T-CELL FACTOR-4; WNT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; EXONS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MICE; MICE, NUDE; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 84885180273     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12189     Document Type: Article

References (36)

1. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
2. Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 2009; 4: 307-12.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
4. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-15.
5. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 2011; 21: 44-58.
6. Kim M, Lee HC, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 2008; 48: 780-91.
7. Tsedensodnom O, Koga H, Rosenberg SA, et al. Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp Cell Res 2011; 317: 920-31.
8. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24.
9. Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004; 127: 1110-22.
10. Nambotin SB, Wands JR, Kim M. Points of therapeutic intervention along the Wnt signaling pathway in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11: 549-59.
11. Kobayashi N, Miyazaki M, Fukaya K, et al. Transplantation of highly differentiated immortalized human hepatocytes to treat acute liver failure. Transplantation 2000; 69: 202-7.
12. Yano H, Iemura A, Fukuda K, et al. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 1993; 18: 320-7.
13. Koga H, Tsedensodnom O, Tomimaru Y, et al. Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. PLoS ONE 2012; 7: e39981.
14. Jho EH, Zhang T, Domon C, et al. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172-83.
15. Longo KA, Kennell JA, Ochocinska MJ, et al. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 2002; 277: 38239-44.
16. El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland P. Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors. J Biol Chem 2001; 276: 41675-82.
17. Shulewitz M, Soloviev I, Wu T, et al. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 2006; 25: 4361-9.
18. Takemaru KI, Moon RT. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 2000; 149: 249-54.
19. Brantjes H, Roose J, van De Wetering M, Clevers H. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res 2001; 29: 1410-9.
20. Gasperowicz M, Otto F. Mammalian Groucho homologs: redundancy or specificity? J Cell Biochem 2005; 95: 670-87.
21. Daniels DL, Weis WI. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005; 12: 364-71.
22. Najdi R, Syed A, Arce L, et al. A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer. Oncogene 2009; 28: 4133-46.
23. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999; 96: 5522-7.
24. Zhao J, Dong L, Lu B, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008; 135: 956-68.
25. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23.
26. Yang XR, Xu Y, Yu B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009; 15: 5518-27.
27. Lee TK, Castilho A, Cheung VC, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63.
28. Wu Z-Q, Brabletz T, Fearon E, et al. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci USA 2012; 109: 11312-7.
29. Longato L, de la Monte S, Kuzushita N, et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009; 49: 1935-43.
30. Nambotin SB, Tomimaru Y, Merle P, Wands JR, Kim M. Functional consequences of WNT3/Frizzled 7 mediated signaling in non-transformed hepatic cells. Oncogenesis 2012; 1: e31.
31. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006; 119: 2635-41.
32. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008; 24: 7-10.
33. Grosso AR, Martin S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-93.
34. Pettigrew CA, Brown MA. Pre-mRNA splicing aberrations and cancer. Front Biosci 2008; 13: 1090-105.
35. Berasain C, Goni S, Castillo J, et al. Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol 2010; 16: 3091-102.
36. Duval A, Rolland S, Tubacher E, et al. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 2000; 60: 3872-9.